169 related articles for article (PubMed ID: 17967058)
1. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.
Bourara K; Liegler TJ; Grant RM
PLoS Pathog; 2007 Oct; 3(10):1477-85. PubMed ID: 17967058
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA.
Russell RA; Moore MD; Hu WS; Pathak VK
Retrovirology; 2009 Feb; 6():16. PubMed ID: 19216784
[TBL] [Abstract][Full Text] [Related]
5. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
6. Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.
Anderson BD; Ikeda T; Moghadasi SA; Martin AS; Brown WL; Harris RS
Retrovirology; 2018 Dec; 15(1):78. PubMed ID: 30558640
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
[TBL] [Abstract][Full Text] [Related]
8. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1.
McDonnell MM; Crawford KHD; Dingens AS; Bloom JD; Emerman M
mBio; 2020 Apr; 11(2):. PubMed ID: 32345636
[TBL] [Abstract][Full Text] [Related]
10. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
[TBL] [Abstract][Full Text] [Related]
11. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C.
Baumert TF; Rösler C; Malim MH; von Weizsäcker F
Hepatology; 2007 Sep; 46(3):682-9. PubMed ID: 17625792
[TBL] [Abstract][Full Text] [Related]
13. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
Yu Q; Chen D; König R; Mariani R; Unutmaz D; Landau NR
J Biol Chem; 2004 Dec; 279(51):53379-86. PubMed ID: 15466872
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
17. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
18. Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
Nakashima M; Ode H; Kawamura T; Kitamura S; Naganawa Y; Awazu H; Tsuzuki S; Matsuoka K; Nemoto M; Hachiya A; Sugiura W; Yokomaku Y; Watanabe N; Iwatani Y
J Virol; 2016 Jan; 90(2):1034-47. PubMed ID: 26537685
[TBL] [Abstract][Full Text] [Related]
19. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
Bonvin M; Achermann F; Greeve I; Stroka D; Keogh A; Inderbitzin D; Candinas D; Sommer P; Wain-Hobson S; Vartanian JP; Greeve J
Hepatology; 2006 Jun; 43(6):1364-74. PubMed ID: 16729314
[TBL] [Abstract][Full Text] [Related]
20. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]